ERBB2 and neoplasm: We compared the genomic profiles of 49 HER2‐positive and 31 HER2‐negative gastric cancer patients and then examined the potential influences of the genomic differences on tumor progression and treatment responses, including the mechanism underlying anti‐HER2 therapy resistance in gastric cancer patients.